

Special Issue

Vaccine Efficacy and Safety in Transplant Recipients

Message from the Guest Editor

The immune system offers protection against bacterial, viral, and other infections. The immune system, however, may be inadequate in offering complete protection upon its first encounter with highly virulent micro-organisms such as tetanus or SARS-CoV-2. Transplant recipients are treated with immunosuppressive drugs to prevent the rejection of the transplanted organ. As a consequence, regular vaccines, administered at regular doses and intervals, may not be as effective as in healthy individuals. Because of this immunosuppressive treatment, transplant recipients have a higher infection risk but, at the same time, can show a poorer response to vaccination. Therefore, the optimal timing and dosing of vaccination is of utmost importance. We would like to encourage submissions to this Special Issue regarding recent advances in optimizing the vaccination response in transplant recipients, referring to transplants in the broadest sense of the word. Adding new information on this subject may lead to a better understanding of the critical determinants of an effective immune response to vaccination and may aid in the design of optimal vaccination strategies for transplant recipients.

Guest Editor

Prof. Dr. Ger Rijkers

Science and Engineering Department, University College Roosevelt,
4331 CB Middelburg, The Netherlands

Deadline for manuscript submissions

31 January 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/205939

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).